Skip to content

The clinical efficacy of a dermal formulation of Dimethicone in the treatment of plantar dermatitis in children aged two to six years

The clinical efficacy of a dermal formulation of Dimethicone in the treatment of plantar dermatitis in children aged two to six years

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20090808002306N9
Enrollment
30
Registered
2024-03-15
Start date
2024-03-10
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Plantar Dermatitis, JPD. Chronic bullous disease of childhood

Interventions

Control group: Children in the control group could be themselves, with one leg receiving the main treatment (dimethicone-containing cream) and one leg receiving only the base cream..

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
2 Years to 6 Years

Inclusion criteria

Inclusion criteria: All children suffering from juvenile plantar dermatitis (Juvenile Plantar Dermatitis) with mild to moderate involvement who referred to dermatology clinics affiliated to Isfahan University of Medical Sciences between the fall of 1402 and the end of winter 1402 and met the entry criteria as described below. be: 2 to 6-year-old child with a clinical diagnosis of Juvenile Plantar Dermatitis (cracks, roughness, flaking, pain and burning in the soles of the feet) Lack of evidence and history Contact dermatitisChemical Absence of causes of fungal dermatophytic diseases of the skin Not taking other medications to relieve cracking, scaling, pain and burning sensation in the soles of the feet during the last two weeks Consent and informed consent of children's parents to enter this research project

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Child's age, child's sex, height, weight, duration of dermatitis, type of drug intervention / drug-free cream, underlying disease, medications received, foot dermatitis scale score. Timepoint: The soles of the right feet of the eligible people, who were sampled based on the entry criteria using the easy method, as the case (treatment with topical cream of 5% dimethicone twice a day) and the sole of their left foot as the control (treatment with the topical base cream without dimethicone twice a day as standard treatment and current basis) are placed. In this study, by dividing the legs of qualified people into right and left, each child is practically his own witness. Both legs of the study subjects, before the study and one week after using the drug, were evaluated by a dermatologist in terms of severity and severity of the disease, erythema, vesiculation, scaling, and skin cracks, and the information was provided by the student. The final year of pharmacy will be recorded, categorized and analyzed. Method of measurement: The soles of the right feet of the eligible people, who were sampled based on the entry criteria using the easy method, as the case (treatment with topical cream of 5% dimethicone twice a day) and the sole of their left foot as the control (treatment with the topical base cream without dimethicone twice a day as standard treatment and current basis) are placed. In this study, by dividing the legs of qualified people into right and left, each child is practically his own witness. Both legs of the study subjects, before the study and one week after using the drug, were evaluated by a dermatologist in terms of severity and severity of the disease, erythema, vesiculation, scaling, and skin cracks, and the information was provided by the student. The final year of pharmacy will be recorded, categorized and analyzed. For the clinical assessment of the intensity of each symptom and scoring them, the standard rating of dermatitis will be used (4). This gr

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ali Mohammad Sabzghabaee

Esfahan University of Medical Sciences

Sabghaba@gmail.com031337927070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026